Protagenic Therapeutics, Inc. has taken a significant step in its financial strategy by entering into a promissory note agreement with Patness LLC. The company will receive $250,000 under this agreement, which is crucial for its ongoing operations and development efforts.

This move is particularly important as it reflects the challenges faced by companies in the pharmaceutical preparations sector when it comes to securing funding. The agreement includes a simple interest rate of 1.0% per annum and outlines specific repayment terms tied to future capital raises.

Background

Protagenic Therapeutics, Inc. is a Delaware-based company engaged in the pharmaceutical preparations industry, specifically under the SIC code 2834. The company trades under the ticker PTIX on the OTC market. Recent filings indicate that Protagenic is actively managing its financial obligations and exploring opportunities for growth.

What the Filing Says

According to the recent SEC filing, dated November 6, 2026, the promissory note issued to Patness LLC stipulates that the principal amount of $250,000 is due upon the earliest of two conditions: the closing of any equity capital raise of at least $1,000,000 or 180 days from the date of the note. The filing states, "The Borrower may prepay the Note, in whole or in part, at any time and from time to time without premium or penalty." This flexibility may provide Protagenic with additional options as it navigates its financial landscape.

Impact

This financial maneuver may impact various stakeholders, including investors and potential partners. The terms of the note reflect the company's need for immediate capital while also providing a pathway for future funding through equity raises. Competitors in the pharmaceutical preparations sector may also take note of this strategy as they consider their own financing options.

What's Next

The filing does not specify what happens next, but it is likely that Protagenic will be focusing on securing additional funding through equity capital raises to meet the conditions outlined in the promissory note.